Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost effectiveness of hepatitis C direct acting agents.

Expert review of pharmacoeconomics & outcomes research - 1 Jun 2024

Shetty Akshay, Lee Michelle, Valenzuela Julia, Saab Sammy

Abstract excerpt

INTRODUCTION: Introduction of direct acting antivirals (DAA) has transformed treatment of chronic hepatitis C (HCV) and made the elimination of HCV an achievable goal set forward by World Health Organization by 2030. Multiple barriers need to be overcome for successful eradication of HCV. Availability of pan-genotypic HCV regimens has decreased the need for genotype testing but maintained high efficacy associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost-Benefit Analysis
Share to Health Policy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Health Services Accessibility

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Mass Screening

Source

Identifiers

PMID: 38665122
DOI: 10.1080/14737167.2024.2348053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost effectiveness of hepatitis C direct acting agents.PMID 38665122Read ↗

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.Semantic proximity Read ↗

Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.Semantic proximity Read ↗

Hepatitis C virus elimination: So close, so far?Semantic proximity Read ↗

Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

What is (cost) effective in patients with chronic hepatitis C virus infection?Semantic proximity Read ↗

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity Read ↗

Pan‐genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high‐ and low‐income regionsSemantic proximity Read ↗

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read ↗

The direct-medical costs associated with interferon-based treatment for Hepatitis C in VietnamSemantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of GeorgiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.